Private Advisor Group LLC Acquires 13,289 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Private Advisor Group LLC lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 18.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 85,036 shares of the company’s stock after buying an additional 13,289 shares during the period. Private Advisor Group LLC’s holdings in CRISPR Therapeutics were worth $3,347,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at $40,000. Darwin Wealth Management LLC acquired a new position in CRISPR Therapeutics during the 3rd quarter worth approximately $43,000. Highline Wealth Partners LLC acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth $39,000. Western Pacific Wealth Management LP boosted its stake in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. Finally, Spire Wealth Management boosted its position in CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after buying an additional 1,482 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Trading Down 5.0 %

Shares of CRISPR Therapeutics stock opened at $47.91 on Monday. The business’s 50-day moving average price is $42.25 and its 200-day moving average price is $46.03. The firm has a market capitalization of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of recent analyst reports. The Goldman Sachs Group cut their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Royal Bank of Canada cut their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Finally, Chardan Capital cut their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $74.40.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.